高级搜索

Linc00460通过海绵吸附影响miR-320a对乳腺癌细胞的有氧糖酵解作用

芮一奇, 邓飞, 王文文, 许华, 李晓伟, 丁永斌, 范姝琳

芮一奇, 邓飞, 王文文, 许华, 李晓伟, 丁永斌, 范姝琳. Linc00460通过海绵吸附影响miR-320a对乳腺癌细胞的有氧糖酵解作用[J]. 肿瘤防治研究, 2022, 49(10): 1037-1042. DOI: 10.3971/j.issn.1000-8578.2022.22.0057
引用本文: 芮一奇, 邓飞, 王文文, 许华, 李晓伟, 丁永斌, 范姝琳. Linc00460通过海绵吸附影响miR-320a对乳腺癌细胞的有氧糖酵解作用[J]. 肿瘤防治研究, 2022, 49(10): 1037-1042. DOI: 10.3971/j.issn.1000-8578.2022.22.0057
RUI Yiqi, DENG Fei, WANG Wenwen, XU Hua, LI Xiaowei, DING Yongbin, FAN Shulin. Effects of Linc00460 on Aerobic Glycolysis in Breast Cancer Cells via Sponge Adsorption of miR-320a[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1037-1042. DOI: 10.3971/j.issn.1000-8578.2022.22.0057
Citation: RUI Yiqi, DENG Fei, WANG Wenwen, XU Hua, LI Xiaowei, DING Yongbin, FAN Shulin. Effects of Linc00460 on Aerobic Glycolysis in Breast Cancer Cells via Sponge Adsorption of miR-320a[J]. Cancer Research on Prevention and Treatment, 2022, 49(10): 1037-1042. DOI: 10.3971/j.issn.1000-8578.2022.22.0057

Linc00460通过海绵吸附影响miR-320a对乳腺癌细胞的有氧糖酵解作用

基金项目: 

苏州市“临床医学专家团队”引进项目 SZYJTD201824

南京医科大学科技发展基金一般项目 NMUB2019265

详细信息
    作者简介:

    芮一奇(1989-),男,硕士,主治医师,主要从事乳腺恶性肿瘤的外科治疗及基础研究

    通讯作者:

    王文文(1984-),女,硕士,副主任医师,主要从事乳腺肿物的微创诊疗和手术治疗,E-mail: 215638381@qq.com

  • 中图分类号: R737.9

Effects of Linc00460 on Aerobic Glycolysis in Breast Cancer Cells via Sponge Adsorption of miR-320a

Funding: 

The Introduction Project of "Clinical Medical Expert Team" of Suzhou SZYJTD201824

The General Project of Science and Technology Development Fund of Nanjing Medical University NMUB2019265

More Information
  • 摘要:
    目的 

    探讨Linc00460通过海绵吸附miR-320a对乳腺癌(BC)细胞有氧糖酵解作用的影响。

    方法 

    qRT-PCR法检测正常乳腺上皮细胞系MCF-10A及5种BC细胞系中Linc00460和miR-320a表达水平。qRT-PCR检测干扰Linc00460对miR-320a表达的影响,双荧光素酶报告基因实验检测miR-320a和Linc00460的靶向关系。将si-Linc00460和miR-320a inhibitor共转染至MDA-MB-231细胞,qRT-PCR检测细胞中miR-320a表达水平;MTT法检测细胞增殖能力;2-NBDG法检测细胞葡萄糖摄取率;比色法检测细胞上清液中乳酸含量;酶活性试剂盒检测糖酵解关键酶的活性;Western blot检测酵解途径中关键蛋白表达水平。

    结果 

    与MCF-10A细胞比较,5种BC细胞系中Linc00460高表达,而miR-320a低表达。干扰Linc00460后,MDA-MB-231细胞中miR-320a表达显著升高。双荧光素酶报告基因实验证实,miR-320a和Linc00460可靶向结合。干扰Linc00460表达后MDA-MB-231细胞增殖能力受到明显抑制(P=0.000),细胞葡萄糖摄取率和细胞上清液中乳酸含量降低(均P=0.000),PFK、PK和LDH酶活性受到抑制(均P=0.000),PFKM、GLUT1和LDHA蛋白表达水平下调(均P=0.000)。抑制miR-320a可明显逆转si-Linc00460对MDA-MB-231细胞增殖和糖酵解的抑制作用(均P=0.000或0.001)。

    结论 

    Linc00460可能通过海绵吸附miR-320a,上调PFKM表达,从而促进BC细胞有氧糖酵解作用。

     

    Abstract:
    Objective 

    To explore the effect of Linc00460 on the aerobic glycolysis of breast cancer (BC) cells through sponge adsorption of miR-320a.

    Methods 

    The qRT-PCR method was used to detect Linc00460 and miR-320a expression levels in normal breast epithelial cell line MCF-10A and five BC cell lines. The effect of interfering Linc00460 on miR-320a expression was detected by qRT-PCR. The double luciferase reporter gene experiment was used to analyze the targeting relationship between miR-320a and Linc00460. In addition, the si-Linc00460 and miR-320a inhibitor were co-transfected into MDA-MB-231 cells, and the expression level of miR-320a in the cells was detected by qRT-PCR; cell proliferation ability was measured by the MTT method; glucose uptake rate was detected by 2-NBDG method; the content of lactic acid in the cell supernatant was detected by colorimetric method; the key enzymes of glycolysis was detected by the enzyme activity kit; and the expression levels of the key proteins in the glycolysis pathway were detected by Western blot.

    Results 

    Linc00460 was highly expressed in five BC cell lines, while miR-320a was lowly expressed as compared with MCF-10A cells. The expression of miR-320a in MDA-MB-231 cells significantly increased after interfering with Linc00460. The double luciferase reporter gene experiment confirmed that miR-320a and Linc00460 could target binding. Interfering with the expression of Linc00460 could inhibit MDA-MB-231 cells proliferation (all P=0.000), reduce the rate of cellular glucose uptake and the content of lactic acid in the cell supernatant (all P=0.000), inhibit the activities of PFK, PK, and LDH enzymes (all P=0.000), and downregulate the protein expression levels of PFKM, GLUT1, and LDHA (all P=0.000). Meanwhile, inhibition of miR-320a could reverse the inhibitory effect of si-Linc00460 on the proliferation and glycolysis of MDA-MB-231 cells (all P=0.000 or 0.001).

    Conclusion 

    Linc00460 might adsorb miR-320a, consequently leading to upregulation of PFKM expression, thereby promoting aerobic glycolysis in BC cells.

     

  • 乳腺癌(breast cancer, BC)是全球女性最常见的恶性肿瘤之一。目前,BC的治疗主要有手术切除、放化疗、内分泌治疗、靶向治疗等。然而,由于BC发病机制复杂,化疗效果不理想,复发率较高[1-2]。研究表明,lncRNAs可通过与特定的目标DNA、RNA和(或)蛋白质结合而发挥作用,广泛参与肿瘤发生发展的调控[3]。已有研究发现,Linc00460是一种lncRNA,在BC中高表达,并与患者不良预后显著相关,其过表达促进BC细胞增殖、侵袭与转移[3],而且可能是BC患者预后的潜在生物标志物[1]。有研究报道,miR-320a作为抑癌因子,可通过靶向胰岛素样生长因子1受体(insulin-like growth factor 1 receptor, IGF-1R)和异黏蛋白(metadherin,MTDH)抑制BC细胞的生长和转移[4-5]。另有研究报道,miR-320a可以靶向调控糖酵解限速酶肌肉磷酸果糖激酶(muscle phosphofructokinase, PFKM)抑制细胞糖酵解,其表达下调可能与肺腺癌的发展直接相关[6]。众所周知,LncRNA常以ceRNA方式作为“海绵”吸附miRNA,阻断miRNA对其下游靶基因的调控作用。目前,在BC细胞中Linc00460、miR-320a及其与糖酵解之间的关系尚不清楚。本研究拟检测BC细胞系中Linc00460和miR-320a表达情况,通过双荧光素酶报告基因实验验证miR-320a和Linc00460靶向结合关系,并进一步探讨Linc00460是否通过海绵吸附miR-320a导致PFKM表达上调,从而促进BC细胞有氧糖酵解作用。

    人乳腺正常上皮细胞MCF-10A及5种乳腺癌细胞系(MCF-7、MDA-MB-231、BT-20、SK-BR-3、MDA-MB-453)购自美国模式培养物保藏中心。胎牛血清购自美国HyClone公司;RPMI1640培养基购自美国Gibco公司;Lipofectamine 2000和BCA蛋白浓度测定试剂盒购自美国Thermo Fisher公司;引物序列均由上海生工公司合成;si-Linc00460及其阴性对照(si-NC)和miR-320a inhibitor及其阴性对照(inhibitor-NC)由苏州金唯智公司设计合成;双荧光素酶报告基因系统购自美国Promega公司;TRIzol和反转录试剂盒购自日本Takara公司;实时荧光定量聚合酶链反应试剂盒购自美国Applied Biosystems公司;MTT试剂购自北京梦怡美生物技术有限公司;Cell MeterTM 2-NBDG葡萄糖摄取检测试剂盒购自美国AAT Bioquest公司;乳酸检测试剂盒、磷酸果糖激酶(PFK)活性检测试剂盒、丙酮酸激酶(PK)活性检测试剂盒和乳酸脱氢酶(LDH)活性检测试剂盒均购自北京索莱宝科技有限公司;GAPDH抗体购自美国Santa Cruz公司;葡萄糖转运蛋白1(GLUT1)抗体和乳酸脱氢酶A(LDHA)抗体购自美国CST公司;肌肉磷酸果糖激酶(PFKM)抗体购自美国Novus Biologicals公司。

    人乳腺正常上皮细胞MCF-10A及5种BC细胞系(MCF-7、MDA-MB-231、BT-20、SK-BR-3、MDA-MB-453)均用含有10%胎牛血清的fRPMI1640培养基培养,置于37℃、5%CO2的培养箱中培养。取对数生长期MDA-MB-231细胞以每孔2×105个细胞浓度接种于6孔板中分组培养,待细胞融合度达到80%左右时,按照Lipofectamine 2000试剂盒说明书进行转染操作,将si-NC(si-NC组)、si-Linc00460(si-Linc00460组)、si-Linc00460与inhibitor-NC(si-Linc00460+inhibitor-NC组)、si-Linc00460与miR-320a inhibitor(si-Linc00460+miR-320a inhibitor组)分别转染至MDA-MB-231细胞中,另设置空白对照组(blank组)。转染48 h后,qRT-PCR检测Linc00460和miR-320a的表达水平以验证转染效果。

    根据TRIzol试剂说明书提取总RNA。以Oligo(dT)为引物,使用反转录酶合成cDNA。使用SYBR反应体系,进行实时定量聚合酶链反应(qRT-PCR)。Linc00460引物:5'-AATGGTGGTAGGAGGGAGGA-3'(正向)和5'-CAAGGGGAATGAACACGAGG-3'(反向);GAPDH引物:5'-GGGAGCCAAAAGGGTCA-3'(正向)和5'-GAGTCCTTCCACGATACCAA-3'(反向);miR-320a引物:5'-GGGCTAAAAGCTGGGTTGA-3'(正向)和5'-CAGTGCGTGTCGTGGAGT-3'(反向);U6引物:5'-GCTTCGGCAGCACATATACT-3'(正向)和5'-GTGCAGGGTCCGAGGTATTC-3'(反向)。qRT-PCR反应条件:94℃预变性5 min,94℃变性30 s、55℃退火30 s、72℃延伸90 s,40个循环。GAPDH和U6分别用作检测lnc-RNA和miRNA的内参,采用2-ΔΔCt法计算各组细胞中Linc00460和miR-320a相对表达量。

    通过ENCORI数据库预测Linc00460和miR-320a之间的结合位点。合成包含miR-320a假定结合位点的Linc00460 3’-UTR序列并将其构建到双荧光素酶载体上,作为Linc00460-WT。同时对假定的结合位点进行突变,作为Linc00460-MUT。然后使用Lipofectamine 2000将报告质粒Linc00460-WT或Linc00460-MUT和miR-320a mimic或阴性对照miR-NC共转染MDA-MB-231细胞。根据试剂盒说明书在转染48 h后测定各组细胞中海肾荧光素酶和萤火虫荧光素酶活性,计算相对荧光素酶活性。

    将转染后各组细胞以每孔1.5×104个接种在96孔板中分别培养12、24、48、72 h,在各时间点前4 h每孔分别加入20 μl MTT继续培养4 h,弃掉孔内液体,每孔加150 μl DMSO充分溶解,用酶标仪在490 nm处测定各孔的OD值,用OD490值表示各组细胞增殖活性。

    将转染后各组细胞以每孔1.5×105个接种到6孔板中。当细胞汇合度达到80%时,用无血清培养基处理细胞4 h,然后用含5%胎牛血清的培养基处理24 h,加入1 ml 2.5 µg/ml浓度2-NBDG溶液处理30 min,PBS洗涤细胞3次,收集细胞,流式细胞仪测量荧光值,根据荧光值计算相对葡萄糖摄取量。将细胞接种于6孔板中,用完全培养基培养24 h后,收集细胞培养液,采用乳酸含量检测试剂盒检测乳酸水平。

    将转染后各组细胞以每孔1×105个接种到6孔板中。培养24 h后收集细胞沉淀,加入适量的蛋白提取液,冰上超声破碎,8 000 g 4℃离心10 min,取细胞上清液,相应的试剂盒检测各组PFK、PK和LDH酶活性水平。

    裂解缓冲液裂解各组细胞,冰上超声破碎提取总蛋白并定量。SDS-PAGE分离蛋白并转移至PVDF膜。PVDF膜用5%牛血清白蛋白封闭2 h,并用适当的一抗GLUT1(1:1 000)、LDHA(1:1 000)、PFKM(1:1 000)和GAPDH(1:1 000)4℃摇晃过夜,加入辣根过氧化物酶(HRP)偶联的二抗(1:10 000)室温孵育1 h,ECL孵育后用显影仪曝光。利用Image J软件对蛋白条带进行定量分析。

    采用SPSS20.0软件进行统计学分析,数据以均数±标准差(x±s)表示,多组间比较采用单因素方差分析,组内比较采用LSD-t检验。P < 0.05为差异有统计学意义。

    与MCF-10A相比,MCF-7、MDA-MB-231、BT-20、SK-BR-3和MDA-MB-453中Linc00460表达水平均显著升高(P=0.000),而miR-320a表达水平均显著降低(P=0.000),其中MDA-MB-231细胞最为显著,见图 1。后续选取MDA-MB-231细胞进行实验。

    图  1  乳腺癌细胞系中Linc00460和miR-320a表达水平
    **: P < 0. 01, ***: P < 0. 001, compared with MCF-10A cells.
    Figure  1  Expression levels of Linc00460 and miR-320a in breast cancer cell lines

    qRT-PCR结果显示,与blank组或si-NC组比较,si-Linc00460组MDA-MB-231细胞中Linc00460表达水平明显下降(P=0.000),而miR-320a表达水平明显上升(P=0.000),见图 2A。ENCORI数据库在线预测显示,miR-320a与Linc00460 3’-UTR区域存在结合位点,见图 2B。进一步双荧光素酶报告基因实验结果证实,与miR-NC组比较,在共转染Linc00460-WT质粒的细胞中,miR-320a mimic组细胞的相对荧光素酶活性显著降低(P=0.004);而在共转染Linc00460-MUT质粒的细胞中,miR-320a mimic组细胞的相对荧光素酶活性无明显差异(P > 0.05),见图 2C

    图  2  Linc00460和miR-320a靶向关系
    A: the expression levels of Linc00460 and miR-320a were detected by qRT-PCR, ***: P < 0. 001, compared with blank or si-NC group; B: bioinformatics prediction of binding sites; C: luciferase reporter gene assay, **: P < 0. 01, compared with miR-NC group.
    Figure  2  Targeting relationship between Linc00460 and miR-320a

    qRT-PCR结果显示,与si-NC组比较,si-Linc00460组MDA-MB-231细胞中miR-320a表达水平显著上升(P=0.000),而与si-Linc00460组或si-Linc00460+inhibitor-NC组比较,si-Linc00460+miR-320a inhibitor组miR-320a表达水平显著降低(均P=0.000),见图 3

    图  3  各组细胞中miR-320a表达水平
    ***: P < 0.001, compared with si-NC group; ###: P < 0.001, compared with si-Linc00460 group or si-Linc00460+inhibitor-NC group; a: si-NC; b: si-Linc00460; c: si-Linc00460+inhibitor-NC; d: si-Linc00460+miR-320a inhibitor.
    Figure  3  Expression level of miR-320a in each group

    MTT检测结果显示,细胞培养24 h后,与si-NC组比较,si-Linc00460组各时间点MDA-MB-231细胞增殖能力明显降低(均P=0.000),而与si-Linc00460组或si-Linc00460+inhibitor-NC组比较,si-Linc00460+miR-320a inhibitor组各时间点MDA-MB-231细胞增殖能力明显升高(P=0.004、0.001、0.000),见图 4

    图  4  MTT检测各组细胞增殖能力
    ***: P < 0.001, compared with si-NC group; ##: P < 0.01, compared with si-Linc00460 group or si-Linc00460+inhibitor-NC group.
    Figure  4  Detection of cell proliferation ability in each group by MTT

    与si-NC组比较,si-Linc00460组MDA-MB-231细胞葡萄糖摄取率显著降低(P=0.000),而与si-Linc00460组或si-Linc00460+inhibitor-NC组比较,si-Linc00460+miR-320a inhibitor组MDA-MB-231细胞葡萄糖摄取率显著升高(均P=0.001),见图 5A。与si-NC组比较,si-Linc00460组MDA-MB-231细胞上清液中乳酸含量显著降低(P=0.000),而与si-Linc00460组或si-Linc00460+inhibitor-NC组比较,si-Linc00460+miR-320a inhibitor组MDA-MB-231细胞上清液中乳酸含量显著升高(均P=0.001),见图 5B

    图  5  各组细胞葡萄糖摄取能力和细胞上清液中乳酸含量
    A: Glucose uptake rate of cells was detected by 2-NBDG method; B: The content of lactic acid in cell supernatant was detected by colorimetry. ***: P < 0.001, compared with si-NC group; ##: P < 0.01, compared with si-Linc00460 group or si-Linc00460+inhibitor-NC group; a: si-NC; b: si-Linc00460; c: si-Linc00460+inhibitor-NC; d: si-Linc00460+miR-320a inhibitor.
    Figure  5  Cell glucose uptake capacity and content of supernatant lactic acid in each group

    与si-NC组比较,si-Linc00460组MDA-MB-231细胞PFK、PK和LDH酶活性明显降低(均P=0.000),而与si-Linc00460组或si-Linc00460+inhibitor-NC组比较,si-Linc00460+miR-320a inhibitor组MDA-MB-231细胞PFK、PK和LDH酶活性显著升高(P=0.001、0.000、0.000),见图 6

    图  6  各组糖酵解关键酶PFK、PK和LDH酶活性
    **: P < 0.01, compared with si-NC group; ##: P < 0.01, compared with si-Linc00460 group or si-Linc00460+inhibitor-NC group; a: si-NC; b: si-Linc00460; c: si-Linc00460+inhibitor-NC; d: si-Linc00460+miR-320a inhibitor.
    Figure  6  Activities of glycolysis enzymes PFK, PK and LDH in each group

    Western blot结果显示,与si-NC组比较,si-Linc00460组MDA-MB-231细胞PFKM、GLUT1和LDHA蛋白表达量显著降低(均P=0.000),而与si-Linc00460组或si-Linc00460+inhibitor-NC组比较,si-Linc00460+miR-320a inhibitor组MDA-MB-231细胞PFKM、GLUT1和LDHA蛋白表达量显著升高(均P=0.000),见图 7

    图  7  各组细胞中PFKM、GLUT1和LDHA蛋白表达水平
    **: P < 0.01, compared with si-NC group; ##: P < 0.01, compared with si-Linc00460 group; a: si-NC; b: si-Linc00460; c: si-Linc00460+inhibitor-NC; d: si-Linc00460+miR-320a inhibitor.
    Figure  7  Protein expression levels of PFKM, GLUT1 and LDHA in each group

    Linc00460是人类lncRNA基因,由染色体13q33.2转录而来,长度为913 bp,由三个外显子组成,缺乏编码能力。Linc00460被看作致癌基因,其作为竞争性内源性RNA(ceRNA)发挥作用,充当miRNA海绵,竞争性与miRNA结合,影响miRNA与其靶基因结合,从而导致靶基因的表达水平升高。Linc00460通过这种miRNA分子海绵效应参与肿瘤进展,如促进增殖活性、上皮间质转化、迁移、侵袭和转移等[7]。例如,在膀胱癌细胞中,Linc00460通过吸附miR-612增加叉头框蛋白(forkhead box K1, FOXK1)表达水平,从而促进细胞增殖和迁移[8];在结直肠癌细胞中,Linc00460通过吸附miR-149-5p促进BGN(Biglycan)表达水平升高,从而促进体外结直肠癌的转移[9];在宫颈癌、胰腺癌和头颈部鳞状细胞癌中,Linc00460也是通过吸附miRNA导致miRNA的靶基因表达上调,从而促进肿瘤细胞的生长[10-12]。此外,研究发现Linc00460在BC中高表达,促进细胞在体外和体内的增殖、迁移和侵袭[4]

    癌症代谢最显著的特征是即使在氧气充足的条件下,大多数癌细胞也更多地选择糖酵解途径获取能量[13-14]。越来越多的证据表明,miRNA与癌基因/肿瘤抑制因子相互作用并影响癌细胞中的糖酵解[15]。有研究报道,miR-320a可以靶向调控糖酵解限速酶PFKM,抑制细胞糖酵解。与正常人肺组织相比,肺腺癌组织中糖酵解限速酶PFKM和LDHA以及乳酸含量显著增加,而miR-320a表达水平的下调可能与细胞糖酵解的诱导有关,从而促进肺腺癌的发展[6]。另有研究报道,Linc00460可以通过吸附miR-320a促进胶质瘤细胞增殖、迁移和侵袭[16]。目前,在BC细胞中Linc00460与糖酵解之间的作用尚不清楚。本研究首先用qRT-PCR分析正常乳腺上皮细胞MCF-10A和BC细胞株MCF-7、MDA-MB-231、BT-20、SK-BR-3和MDA-MB-453中Linc00460和miR-320a的表达水平,结果显示,与正常乳腺上皮细胞MCF-10A相比,5种BC细胞株中Linc00460表达水平均明显上调,而miR-320a表达水平均明显下调。干扰Linc00460表达后,MDA-MB-231细胞中miR-320a表达水平显著上升。ENCORI数据库预测miR-320a与Linc00460 3’-UTR区域存在结合位点,进一步通过双荧光素酶报告基因实验证实miR-320a可以与Linc00460靶向结合。

    本研究发现干扰Linc00460表达后,MDA-MB-231细胞增殖活性明显降低,细胞葡萄糖摄取率和细胞上清液中乳酸含量显著降低,糖酵解关键酶PFK、PK和LDH酶活性也明显降低;而抑制miR-320a表达可以减弱干扰Linc00460表达对MDA-MB-231细胞增殖活性和糖酵解的抑制。进一步检测发现,干扰Linc00460表达后,miR-320a的靶基因糖酵解关键蛋白PFKM蛋白表达量显著降低,其他糖酵解相关蛋白GLUT1和LDHA蛋白表达量也显著降低;同时抑制miR-320a可明显逆转PFKM、GLUT1和LDHA蛋白的表达。结果提示Linc00460可能通过吸附miR-320a,上调PFKM表达,从而促进BC细胞有氧糖酵解作用。

    综上所述,在BC细胞系中Linc00460高表达,而miR-320a低表达。Linc00460作为ceRNA发挥作用,通过吸附miR-320a上调PFKM表达,从而促进BC细胞有氧糖酵解作用,可以作为BC的潜在治疗靶点。

    Competing interests: The authors declare that they have no competing interests.
    作者贡献:
    芮一奇:实验实施、文章撰写、经费支持
    邓飞:实验实施、数据采集
    王文文:实验设计、文章审阅、数据分析
    许华、李晓伟、丁永斌:实验实施、数据分析
    范姝琳:实验指导、统计学分析、英文摘要撰写
  • 图  1   乳腺癌细胞系中Linc00460和miR-320a表达水平

    Figure  1   Expression levels of Linc00460 and miR-320a in breast cancer cell lines

    图  2   Linc00460和miR-320a靶向关系

    Figure  2   Targeting relationship between Linc00460 and miR-320a

    图  3   各组细胞中miR-320a表达水平

    Figure  3   Expression level of miR-320a in each group

    图  4   MTT检测各组细胞增殖能力

    Figure  4   Detection of cell proliferation ability in each group by MTT

    图  5   各组细胞葡萄糖摄取能力和细胞上清液中乳酸含量

    Figure  5   Cell glucose uptake capacity and content of supernatant lactic acid in each group

    图  6   各组糖酵解关键酶PFK、PK和LDH酶活性

    Figure  6   Activities of glycolysis enzymes PFK, PK and LDH in each group

    图  7   各组细胞中PFKM、GLUT1和LDHA蛋白表达水平

    Figure  7   Protein expression levels of PFKM, GLUT1 and LDHA in each group

  • [1]

    Wang X, Gao C, Feng F, et al. Construction and analysis of competing endogenous RNA networks for breast cancer based on TCGA dataset[J]. Biomed Res Int, 2020, 2020: 4078596.

    [2]

    Morales MAG, Rodríguez RB, Cruz JRS, et al. Overview of new treatments with immunotherapy for breast cancer and a proposal of a combination therapy[J]. Molecules, 2020, 25(23): 5686. doi: 10.3390/molecules25235686

    [3]

    Zhu Y, Yang L, Chong QY, et al. Long noncoding RNA Linc00460 promotes breast cancer progression by regulating the miR-489-5p/FGF7/AKT axis[J]. Cancer Manag Res, 2019, 11: 5983-6001. doi: 10.2147/CMAR.S207084

    [4]

    Guan J, Zhou Y, Mao F, et al. MicroRNA-320a suppresses tumor cell growth and invasion of human breast cancer by targeting insulin-like growth factor 1 receptor[J]. Oncol Rep, 2018, 40(2): 849-858.

    [5]

    Yu J, Wang JG, Zhang L, et al. MicroRNA-320a inhibits breast cancer metastasis by targeting metadherin[J]. Oncotarget, 2016, 7(25): 38612-38625. doi: 10.18632/oncotarget.9572

    [6]

    Tang H, Lee M, Sharpe O, et al. Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems[J]. FASEB J, 2012, 26(11): 4710-4721. doi: 10.1096/fj.11-197467

    [7]

    Cisneros-Villanueva M, Hidalgo-Pérez L, Cedro-Tanda A, et al. LINC00460 is a dual biomarker that acts as a predictor for increased prognosis in basal-like breast cancer and potentially regulates immunogenic and differentiation-related genes[J]. Front Oncol, 2021, 11: 628027. doi: 10.3389/fonc.2021.628027

    [8]

    Li J, Huang S, Zhang Y, et al. LINC00460 enhances bladder carcinoma cell proliferation and migration by modulating miR-612/FOXK1 axis[J]. Pharmacology, 2021, 106(1-2): 79-90. doi: 10.1159/000509255

    [9]

    Ruan T, Lu S, Xu J, et al. lncRNA LINC00460 functions as a competing endogenous RNA and regulates expression of BGN by Sponging miR-149-5p in colorectal cancer[J]. Technol Cancer Res Treat, 2021, 20: 1533033820964238.

    [10]

    Li F, Zhu W, Wang Z, et al. Long noncoding RNA LINC00460 promotes the progression of cervical cancer via regulation of the miR-361-3p/Gli1 axis[J]. Hum Cell, 2021, 34(1): 229-237. doi: 10.1007/s13577-020-00447-2

    [11]

    Cheng J, Lou Y, Jiang K, et al. Downregulation of long non-coding RNA LINC00460 inhibits the proliferation, migration and invasion, and promotes apoptosis of pancreatic cancer cells via modulation of the miR-320b/ARF1 axis[J]. Bioengineered, 2021, 12(1): 96-107. doi: 10.1080/21655979.2020.1863035

    [12]

    Yang Y, Wang R, Feng L, et al. LINC00460 promotes cell proliferation, migration, invasion, and epithelial-mesenchymal transition of head and neck squamous cell carcinoma via miR-320a/BGN axis[J]. Onco Targets Ther, 2021, 14: 2279-2291. doi: 10.2147/OTT.S282947

    [13]

    Zhou Y, Lin F, Wan T, et al. ZEB1 enhances Warburg effect to facilitate tumorigenesis and metastasis of HCC by transcriptionally activating PFKM[J]. Theranostics, 2021, 11(12): 5926-5938. doi: 10.7150/thno.56490

    [14]

    Gao W, Huang M, Chen X, et al. The role of S-nitrosylation of PFKM in regulation of glycolysis in ovarian cancer cells[J]. Cell Death Dis, 2021, 12(4): 408.

    [15]

    Yu L, Chen X, Wang L, et al. The sweet trap in tumors: aerobic glycolysis and potential targets for therapy[J]. Oncotarget, 2016, 7(25): 38908-38926.

    [16]

    Feng L, Rao M, Zhou Y, et al. Long noncoding RNA 00460 (LINC00460) promotes glioma progression by negatively regulating miR-320a[J]. J Cell Biochem, 2019, 120(6): 9556-9563.

图(7)
计量
  • 文章访问数:  1373
  • HTML全文浏览量:  418
  • PDF下载量:  214
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-01-13
  • 修回日期:  2022-06-06
  • 网络出版日期:  2024-01-12
  • 刊出日期:  2022-10-24

目录

/

返回文章
返回
x 关闭 永久关闭